is...(horny for cash)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CANOPY GROWTH INSIDERS GETTING RID OF THEIR SHARES..... moveing to ACB LOLOLOLOL jk not sure
Updated Friday Jun 28, 2019 01:41 AM EDT
Bruce Linton, CEO, Director and 10% Holder, disposed of 347,736 Common Shares on a direct ownership basis at prices ranging from $51.200 to $51.924 on June 26th, 2019. This represents a $17,965,850 divestment of the company's shares and an account share holdings change of -59.0%.
On the same day, Mark Anthony Nicholas Zekulin, a Senior Officer, disposed of 100,000 Common Shares on a direct ownership basis at a price of $51.773. This represents a $5,177,270 divestment of the company's shares and an account share holdings change of -41.5%.
Timothy Rob Saunders, CFO, disposed of 91,666 Common Shares on a direct ownership basis at prices ranging from $51.339 to $51.535 on June 26th, 2019. This represents a $4,715,822 divestment of the company's shares and an account share holdings change of -100.0%.
David Bigioni, a Senior Officer, disposed of 3,600 Common Shares on a control or direction basis for registered holder Jennifer Elaine Bigioni at a price of $52.100 on June 27th, 2019. This represents a $187,560 divestment of the company's shares and an account share holdings change of -93.5%.
Canopy Growth is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
Canopy Growth Corp, formerly Tweed Marijuana Inc, is a Canada-based multi-brand cannabis company. The Company, through its subsidiaries Tweed Inc, Bedrocan Canada Inc, Tweed Farms Inc and Mettrum Health Corp is engaged in the business of producing and selling legal marijuana in the Canadian medical market. It is also focusing on producing and selling marijuana in the recreational market in Canada. Its core brands are Tweed and Bedrocan. Tweed is a licensed producer of medical marijuana. Tweed's commercial license covers approximately 168,000 square feet of its Smiths Falls facility and allows Tweed to produce and sell approximately 3,540 kilograms of medical marijuana per year. Tweed's built-out production capacity is over 10 climate controlled indoor growing rooms. Bedrocan is a medical-grade cannabis. Bedrocan's over 52,000 square feet production facility in Toronto, Ontario is licensed, and includes over 30 vegetative and growing rooms, and over three dispensing rooms.
MorningStar and the Empire
Not planning to sell this one for years to come!!!!!! ENWAVE shares are going to be so valuable!!!
EnWave and Aurora Cannabis Expand Scope of Machine Delivery to Achieve Good Manufacturing Practice (GMP) Standards
Source: GlobeNewswire Inc.
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) reports today that Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) (NYSE: ACB), is expanding the scope of requirements for its potential purchase of a third 120kW Radiant Energy Vacuum (“REV™”) machine targeted for its European operations in Denmark. Aurora Nordic Cannabis, a subsidiary of Aurora, plans to develop a pharmaceutical-level GMP facility, which requires several upgrades to the contemplated machinery. These upgrades will be confirmed as soon as possible and will also increase the economic profile of this prospective equipment purchase.
On April 26, 2019, EnWave and Aurora announced that the companies had entered into a royalty-bearing commercial license agreement with sub-licensing rights, providing Aurora with the exclusive rights to EnWave’s patented REV™ drying technology for the production of cannabis materials in the European Union, excluding Portugal (the “European License”).
Aurora intends to pursue widespread adoption of the REV™ technology throughout its global operations to capture the significant advantages of EnWave’s drying technology when compared to traditional drying methods.
Benefits of REV™ Technology in the Cannabis Industry
EnWave’s patented REV™ technology is a rapid, low temperature, continuous drying method that maintains optimal terpene levels, flavour, as well as other product attributes during the drying process. The company’s vacuum-microwave technology enables fast, uniform drying with flexible final moisture content; capabilities that are unattainable with freeze drying or air drying.
In the cannabis industry, REV™ technology provides for capital expenditure savings on drying space (smaller footprint) and related HVAC investments, as well as the ability to free up space, which can be repurposed to increase the economic output of each facility. Furthermore, EnWave’s REV™ technology reduces drying time from 5-7 days to less than two hours, resulting in significant working capital savings and speed to market of product. The technology has certain additional benefits, including the support of industrial scale flow-though, accelerating the ability for large-scale processing of cannabis and CBD-rich biomass into intermediate or finished product.
About EnWave
EnWave Corporation, a Vancouver-based advanced technology company, has developed Radiant Energy Vacuum (“REV™”) – an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV™ technology, shortening the time from harvest to marketable cannabis products.
REV™ technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with industry leaders in multiple verticals for the use of REV™ technology. The company has signed over twenty royalty-bearing licenses to date, opening up nine distinct market sectors for commercialization of new and innovative products. In addition to these licenses, EnWave has formed a Limited Liability Corporation, NutraDried Food Company, LLC, to develop, manufacture, market and sell all-natural cheese snack products in the United States under the Moon Cheese® brand.
EnWave has introduced REV™ as the new dehydration standard in the food and biological material sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently has three commercial REV™ platforms:
nutraREV® which is used in the food industry to dry food products quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour;
powderREV® which is used for the bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes below the freezing point, and
quantaREV® which is used for continuous, high-volume low-temperature drying.
An additional platform, freezeREV®, is being developed as a new method to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.
EnWave Corporation
Mr. Brent Charleton, CFA
President and CEO
For further information:
Brent Charleton, CFA , President and CEO at +1 (778) 378-9616
E-mail: bcharleton@enwave.net
Dan Henriques, CPA, Chief Financial Officer at +1 (604) 835-5212
E-mail: dhenriques@enwave.net
Deborah Honig, Corporate Development at + 1 (647) 203-8793
E-mail: dhonig@enwave.net
Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third party claims referred to in this release are not guaranteed to be accurate. All third party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. No statement in this press release should be construed as a waiver of any party’s rights, and all such rights are reserved. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Primary Logo
Wow Enwave got good news from
Aurora ACB, We’ll see what happens tomorrow with the news
Nice little up rick 1.61-1.78
Open at $2.10
Strange..... someone dumped
Might just be an early “Good Friday”
61,000@2$ on deck
23,000 just bought at $1.99
98%buys today
Think Mike Tyson just bought 450 acres as well....
March 6th never saw the press release 445 acres bought https://www.google.ca/amp/s/amp.reddit.com/r/weedstocks/comments/axvhi6/aurora_cannabis_acquires_445_acres_in_westwold_bc/
New high today 2.01
If its gonna go its now..... 1.97 bulls in charge
Blue sky tomorrow’s????lots of buyers today
Maybe 2$ in a little bit
$1.96
Looking sharper than ever
$1.93HoD
Huge bounce off $7
Cant wait for the billion $ contracts!!!
Patiently waiting!!!
ACB on track for 700,000 kilos
@$7500 a kilo=$$$$
Cry now laughing later!!
Reminds me of johnny cash...
Down down in the ring of fire
$7.80
Looks like a champ to me! Thanks for the post,,, cant believe its not on their website yet...
Thank you
Maybe they meant may 28th 2025
Must be taking a while to write all them extra zeros under profit line
13 truck loads...... i picture a 1985 Toyota pick up truck ??
Bulls said nope....
Lol, is today the 28th lmao ??
Is it the 28th yet
Aurora Cannabis Inc (ACB) Expected to Announce Quarterly Sales of $91.59 Million
Posted by Denise Davis on May 22nd, 2019
Aurora Cannabis logoEquities research analysts predict that Aurora Cannabis Inc (NYSE:ACB) will announce $91.59 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Aurora Cannabis’ earnings. The lowest sales estimate is $86.07 million and the highest is $98.50 million. Aurora Cannabis reported sales of $14.84 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 517.2%. The company is expected to announce its next quarterly earnings report on Tuesday, September 24th.
According to Zacks, analysts expect that Aurora Cannabis will report full year sales of $205.06 million for the current financial year, with estimates ranging from $198.32 million to $209.33 million. For the next financial year, analysts forecast that the business will post sales of $517.38 million, with estimates ranging from $469.23 million to $619.84 million. Zacks’ sales averages are an average based on a survey of research firms that cover Aurora Cannabis.
Get Aurora Cannabis alerts:
ACB has been the topic of several recent analyst reports. GMP Securities reissued a “hold” rating and set a $9.50 target price on shares of Aurora Cannabis in a research note on Tuesday, February 12th. Seaport Global Securities began coverage on shares of Aurora Cannabis in a research report on Thursday, February 21st. They set a “neutral” rating for the company. Jefferies Financial Group began coverage on shares of Aurora Cannabis in a research report on Monday, February 25th. They set a “buy” rating for the company. TheStreet downgraded shares of Aurora Cannabis from a “c” rating to a “d+” rating in a research report on Monday, February 25th. Finally, Cowen began coverage on shares of Aurora Cannabis in a research report on Tuesday, March 5th. They set an “outperform” rating for the company. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $9.86.
Hedge funds have recently added to or reduced their stakes in the business. Bank of Nova Scotia acquired a new stake in Aurora Cannabis in the 4th quarter valued at about $2,537,000. Deutsche Bank AG purchased a new stake in shares of Aurora Cannabis in the 4th quarter valued at approximately $3,105,000. Virtu Financial LLC purchased a new stake in shares of Aurora Cannabis in the 4th quarter valued at approximately $1,355,000. JW Asset Management LLC purchased a new stake in shares of Aurora Cannabis in the 4th quarter valued at approximately $10,734,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Aurora Cannabis in the 4th quarter valued at approximately $459,000. Institutional investors own 8.35% of the company’s stock.
Shares of ACB stock traded down $0.03 during mid-day trading on Friday, hitting $8.63. 287,791 shares of the stock were exchanged, compared to its average volume of 26,821,131. The company has a quick ratio of 2.50, a current ratio of 2.37 and a debt-to-equity ratio of 0.10. Aurora Cannabis has a 52-week low of $4.05 and a 52-week high of $12.52. The firm has a market cap of $8.82 billion, a P/E ratio of 71.90 and a beta of 2.82.
Aurora Cannabis Company Profile
Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Featured Story: Moving Average (MA)
Get a free copy of the Zacks research report on Aurora Cannabis (ACB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Earnings History and Estimates for Aurora Cannabis (NYSE:ACB)
Clay knows where the money is.....